Last 35 quarters of trend data · Healthcare · Medical - Devices
Quarterly valuation ratios — annualised for comparability. YoY Δ shows same-quarter-prior-year change.
TransMedics Group, Inc.'s quarterly P/E stands at 124.3x, up 417.1% year-over-year — indicating the stock has re-rated higher or earnings have softened. EV/EBITDA has expanded 245.2% YoY to 74.4x, reflecting rising market expectations or slowing EBITDA growth.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| P/E Ratio → | 16.18 | 124.26 | 11.74 | 42.50 | 36.42 | 24.03 | 82.04 | 327.08 | 107.59 | 52.81 | 164.44 | — | — |
| — | +417.1% | -85.7% | -87.0% | -66.2% | -54.5% | -50.1% | — | — | — | — | — | — | |
| P/S Ratio | 4.50 | 5.17 | 7.74 | 7.95 | 8.63 | 4.68 | 4.51 | 12.88 | 11.62 | 6.62 | 8.31 | 6.72 | 13.02 |
| — | +10.6% | +71.6% | -38.3% | -25.7% | -29.3% | -45.7% | +91.6% | -10.7% | -55.0% | -47.2% | -45.3% | +21.5% | |
| P/B Ratio | 6.75 | 7.28 | 10.52 | 12.87 | 17.09 | 10.08 | 9.60 | 26.69 | 27.99 | 16.08 | 19.66 | 14.12 | 18.82 |
| — | -27.8% | +9.6% | -51.8% | -39.0% | -37.3% | -51.2% | +89.0% | +48.7% | +26.8% | +86.5% | +110.2% | +8.9% | |
| P/FCF | 20.38 | — | 65.52 | 18.45 | 16.46 | — | 90.61 | — | 679.68 | — | — | — | — |
| — | — | -27.7% | — | -97.6% | — | — | — | — | — | — | — | — | |
| EV / EBITDA | 19.92 | 74.36 | 43.15 | 38.35 | 32.07 | 21.54 | 41.49 | 159.08 | 79.92 | 40.57 | 113.52 | — | 1371.38 |
| — | +245.2% | +4.0% | -75.9% | -59.9% | -46.9% | -63.5% | — | -94.2% | — | — | — | — | |
| EV / EBIT | 24.91 | 74.36 | 49.63 | 43.60 | 35.01 | 24.00 | 56.27 | 184.13 | 86.66 | 42.68 | 94.37 | — | 437.04 |
| — | +209.8% | -11.8% | -76.3% | -59.6% | -43.8% | -40.4% | — | -80.2% | — | — | — | — |
Quarterly margins and returns. Watch for margin compression across consecutive quarters.
TransMedics Group, Inc.'s operating margin was 7.6% in Q1 2026, down 5.6 pp QoQ and down 11.5 pp YoY. This marks the 4th consecutive quarter of margin compression, signaling a persistent pressure on profitability that investors should monitor. The trailing four-quarter average of 15.1% exceeds the current quarter, suggesting the latest result may reflect seasonal weakness or a one-off headwind. Gross margin contracted 5.4% YoY, suggesting cost inflation or competitive pricing pressure.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | 59.9% | 58.2% | 58.1% | 58.8% | 61.4% | 61.5% | 59.2% | 55.9% | 60.5% | 61.8% | 59.0% | 61.2% | 70.0% |
| — | -5.4% | -1.9% | +5.1% | +1.4% | -0.6% | +0.3% | -8.6% | -13.6% | -10.7% | -10.5% | -13.2% | +0.1% | |
| Operating Margin | 17.9% | 7.6% | 13.2% | 16.2% | 23.2% | 19.1% | 7.1% | 3.6% | 10.9% | 12.8% | 3.2% | -42.7% | -1.7% |
| — | -60.0% | +86.2% | +349.1% | +112.3% | +49.1% | +121.6% | +108.5% | +733.7% | +355.1% | +114.8% | -97.6% | +96.4% | |
| Net Margin | 31.4% | 4.2% | 65.6% | 16.9% | 22.2% | 17.9% | 5.6% | 3.9% | 10.7% | 12.6% | 5.0% | -38.3% | -1.9% |
| — | -76.5% | +1062.7% | +336.2% | +107.9% | +42.1% | +13.5% | +110.1% | +659.1% | +298.5% | +123.2% | -32.4% | +96.6% |
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| ROE | 54.2% | 1.5% | 25.4% | 7.2% | 11.9% | 10.4% | 3.1% | 2.1% | 7.0% | 8.2% | 3.1% | -18.7% | -0.6% |
| — | -85.4% | +713.7% | +242.5% | +71.1% | +26.2% | +2.3% | +111.3% | +1278.0% | +692.7% | +185.4% | -200.9% | +97.2% | |
| ROA | 20.3% | 0.6% | 10.5% | 2.6% | 4.0% | 3.1% | 0.9% | 0.5% | 1.6% | 1.7% | 0.6% | -3.7% | -0.2% |
| — | -81.3% | +1112.8% | +384.9% | +145.6% | +83.4% | +49.3% | +114.8% | +903.3% | +282.6% | +123.7% | +2.7% | +97.9% | |
| ROIC | 18.8% | 1.5% | 3.7% | 4.1% | 6.0% | 4.7% | 1.6% | 0.8% | 2.8% | 3.2% | 0.8% | -14.5% | -1.0% |
| — | -67.2% | +130.5% | +421.4% | +114.7% | +45.8% | +94.5% | +105.5% | +394.2% | +220.5% | +108.5% | -103.5% | +90.0% |
Quarterly solvency trend — watch for debt spikes or covenant pressure.
TransMedics Group, Inc.'s Debt/EBITDA ratio is 61.6x, up from 16.3x last quarter — elevated, raising questions about debt serviceability. The current ratio has weakened 26.0% YoY to 6.74x, tightening the short-term liquidity position.
| Metric | TTM | Q1 '26 | Q4 '25 | Q3 '25 | Q2 '25 | Q1 '25 | Q4 '24 | Q3 '24 | Q2 '24 | Q1 '24 | Q4 '23 | Q3 '23 | Q2 '23 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.99 | 1.66 | 0.99 | 1.46 | 1.63 | 1.95 | 2.27 | 2.47 | 2.72 | 3.24 | 3.76 | 4.08 | 3.55 |
| — | -14.9% | -56.2% | -40.8% | -40.0% | -39.9% | -39.7% | -39.5% | -23.3% | +826.4% | +943.0% | +1030.9% | +301.3% | |
| Debt / EBITDA | 3.46 | 61.57 | 16.34 | 17.23 | 11.98 | 15.44 | 36.18 | 56.94 | 30.19 | 30.69 | 83.11 | — | 1059.69 |
| — | +298.8% | -54.8% | -69.7% | -60.3% | -49.7% | -56.5% | — | -97.2% | — | — | — | — | |
| Current Ratio | 7.14 | 6.74 | 7.14 | 7.69 | 9.86 | 9.10 | 8.30 | 8.20 | 9.37 | 9.72 | 9.30 | 10.93 | 20.70 |
| — | -26.0% | -13.9% | -6.2% | +5.2% | -6.4% | -10.7% | -25.0% | -54.7% | +6.4% | -12.8% | -9.8% | +394.9% | |
| Quick Ratio | 6.59 | 6.19 | 6.59 | 7.13 | 9.17 | 8.32 | 7.52 | 7.33 | 8.48 | 8.76 | 8.49 | 10.13 | 19.74 |
| — | -25.5% | -12.3% | -2.8% | +8.2% | -5.0% | -11.4% | -27.6% | -57.1% | +5.5% | -13.3% | -9.7% | +478.2% | |
| Interest Coverage | 8.80 | 1.85 | 7.45 | 7.60 | 11.41 | 8.71 | 2.96 | 2.17 | 4.35 | 4.44 | 2.07 | -6.50 | 0.61 |
| — | — | — | — | — | — | — | — | — | — | — | — | — |
Includes 30+ ratios · 35 years · Updated daily
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
See how regular investing compounds over time.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying TMDX stock.
TransMedics Group, Inc.'s current P/E is 16.2x. The average P/E over the last 4 quarters is 53.7x. Quarterly P/E ratios can vary due to seasonal revenue patterns and one-time charges.
TransMedics Group, Inc.'s current operating margin is 17.9%. Margins have been compressing over recent quarters. Quarterly margins are particularly useful for identifying trend inflections that annual data smooths over.
Quarterly financial ratios reveal short-term trend shifts — margin compression, debt spikes, or valuation re-ratings — that annual figures smooth over. They're essential for active investors tracking TransMedics Group, Inc.'s business trajectory between earnings reports.